MedPath

DANA-FARBER CANCER INSTITUTE

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
-
Website
http://www.dana-farber.org/

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

Phase 2
Completed
Conditions
Liver Cancer
First Posted Date
2003-04-09
Last Posted Date
2013-07-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
12
Registration Number
NCT00058487
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Phase 3
Completed
Conditions
Graft Versus Host Disease
Interventions
Biological: Daclizumab
Drug: methylprednisolone
Drug: Placebo
First Posted Date
2003-02-06
Last Posted Date
2017-01-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
105
Registration Number
NCT00053976
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

and more 5 locations

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 1
Completed
Conditions
Prostate Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-07-18
Lead Sponsor
Dana-Farber Cancer Institute
Registration Number
NCT00005627
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

Phase 2
Completed
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2018-03-29
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
23
Registration Number
NCT00052611
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Early Phase 1
Terminated
Conditions
Leukemia
Interventions
Biological: CD 40
First Posted Date
2003-01-27
Last Posted Date
2017-06-20
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
9
Registration Number
NCT00020670
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

Phase 2
Completed
Conditions
Veno-occlusive Disease
Interventions
First Posted Date
2003-01-27
Last Posted Date
2017-01-20
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
151
Registration Number
NCT00003966
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital Boston, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 6 locations

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

Phase 2
Completed
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2017-01-19
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
16
Registration Number
NCT00003744
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Lahey Clinic, Burlington, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sarah Cannon Research Institute, Nashville, Tennessee, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 3 locations

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2017-07-11
Lead Sponsor
Dana-Farber Cancer Institute
Registration Number
NCT00047281
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 1
Completed
Conditions
Head and Neck Cancer
Interventions
Drug: Taxotere
Procedure: Surgery
Radiation: radiation therapy
First Posted Date
2003-01-27
Last Posted Date
2017-06-16
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
31
Registration Number
NCT00006107
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2017-07-11
Lead Sponsor
Dana-Farber Cancer Institute
Registration Number
NCT00047294
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath